Jaimy Lee

The FDA re­ject­ed Ap­plied Ther­a­peu­tics’ ex­per­i­men­tal treat­ment for a rare dis­ease called clas­sic galac­tosemia, cit­ing de­fi­cien­cies with the ap­pli­ca­tion. The com­pa­ny, while “dis­ap­point­ed with the

Plus, news about Telios Phar­ma and Celldex Ther­a­peu­tics: An­oth­er day, an­oth­er pub­lic of­fer­ing: Apogee Ther­a­peu­tics is aim­ing to raise $350 mil­lion in a stock sale

Plus, news about Tar­sus Phar­ma­ceu­ti­cals, Hu­ma­cyte, Stem­cell Tech­nolo­gies and SQZ Biotech­nolo­gies: Achieve Life Sci­ences rais­es $124M, de­tails plans for NDA: The com­pa­ny plans to sub­mit

Plus, news about Xen­cor, Ot­su­ka, Type­writer Ther­a­peu­tics, Cas­sa­va Sci­ences, En­ver­ic Bio­sciences, Viking Ther­a­peu­tics and Janux Ther­a­peu­tics: Next up in the PIPE bo­nan­za: RNA com­pa­ny Avid­i­ty

Mile­stone Phar­ma­ceu­ti­cals de­tails plan to re­sub­mit etri­pamil to the FDA in Q2: For its ex­per­i­men­tal treat­ment for parox­ys­mal supraven­tric­u­lar tachy­car­dia, the com­pa­ny will now “re­struc­ture

Plus, news about Telix, QSAM Bio­sciences, Nicox, and Kowa: Eli Lil­ly se­lects Foghorn can­di­date for de­vel­op­ment: Foghorn’s stock $FHTX jumped 16% on Thurs­day morn­ing af­ter

Plus, news about Pep­Gen and Jasper Ther­a­peu­tics: Jazz Phar­ma­ceu­ti­cals buys Redx Phar­ma’s KRAS in­hibitors: The com­pa­ny is pay­ing Redx $10 mil­lion up­front, with mile­stones up

Plus, news about At­tralus, Sang­amo, Mithra, NeOnc, 4D Mol­e­c­u­lar Ther­a­peu­tics and Im­mix Bio­phar­ma: Im­munome buys Ay­ala’s desmoid tu­mor as­set: The biotech will pay $20 mil­lion

Plus, news about An­bo­gen Ther­a­peu­tics and Ve­ra Ther­a­peu­tics: Hutchmed inks deal of up to $227.5M: The com­pa­ny is li­cens­ing two drugs to Im­ma­gene Bio­phar­ma­ceu­ti­cals: IMG-007,

Plus, news about Cor­bus and Astel­las: Halia Ther­a­peu­tics rais­es $30M Se­ries C: The com­pa­ny, which is de­vel­op­ing small mol­e­cules for in­flam­ma­to­ry dis­eases, plans to use